Nanocarriers are microscopic synthetic particles that can deliver therapeutic drugs to a required area in the body. Now researchers say they have developed a new class of nanocarriers, prompting optimism in the long fight against aggressive cases of glioblastoma multiforme.
In a new computational study, researchers at the University of California, San Diego, have discovered a single molecule which was able to shrink a human glioblastoma in a mouse model by half.
Europe's Novocure has won an expanded indication for a 2011 FDA approval of its Optune to treat newly diagnosed glioblastoma in combination with temozolomide, a standard chemotherapy. The company has been on a roll of late, disclosing a CE mark for its second-generation version of Optune on Oct. 5 and pricing a $165 million IPO on Oct. 2.
NovoCure has pulled off an enormous $165 million IPO--but the deal wasn't nearly as large as it had hoped for originally. At the last minute, the brain cancer treatment company kicked its existing investors out of selling their 5 million shares in the offering and it also lowered its share price expectations to $22 from an original range of $26 to $29 each.
Novocure has filed for an IPO to raise up to $300 million on the strength of a potential FDA approval for its Optune device in combination with chemotherapy for patients with newly diagnosed glioblastoma.
R-Biopharm will develop a companion diagnostic for Apogenix's lead anticancer candidate under an agreement the two just signed.
New findings from researchers at the University of California-San Diego School of Medicine and Moores Cancer Center show that cancer stem cell properties are epigenetically controlled in glioblastoma, an aggressive and common form of brain cancer. And they believe their insights point investigators to a promising new drug target.
Celldex has added another round of positive data demonstrating that its brain cancer vaccine rindopepimut--more formally called Rintega and less formally "rindo"--provided a clear though relatively modest average survival benefit for recurrent glioblastoma patients in a Phase II study. And with the initial data set from Phase III looming later in the year, the biotech is carefully moving forward with its ongoing dialogue with regulators to gauge just how receptive they may be to speeding up an approval.
Researchers in Japan have published a study in the journal Science and Technology of Advanced Materials demonstrating greater potential for nanoparticles that can both carry drugs and act as imaging targets to diagnose malignant tumors in the brain.
The FDA has granted priority review status to Novocure's supplemental PMA application for its Optune to treat newly diagnosed glioblastoma in combination with temozolomide chemotherapy. The tumor-treating-fields device is already approved to treat recurrent glioblastoma in adults.